Explore answers to common questions about OncoFirm™ Diagnostics’ fluorescent and lateral flow rapid test technologies, including how these platforms work, biomarker detection, digital reader integration, potential research applications, performance considerations, and regulatory pathways. This FAQ category is intended for general educational and informational purposes and does not represent that any specific OncoFirm™ product is cleared, approved, CE marked, or authorized for clinical use unless expressly stated.
Provide results typically in 5–15 minutes, enabling immediate clinical decisions.
No lab equipment required; can be performed by non-specialists with minimal training.
Low manufacturing and operational costs make them ideal for large-scale screening and use in resource-limited settings.
Compact, lightweight design makes LFTs ideal for point-of-care, home, and mobile clinics.
Often use blood from a finger prick, saliva, urine, or nasal swabs, improving patient comfort and compliance.
Used across multiple fields:
Infectious diseases (COVID-19, flu, HIV)
Chronic conditions (cardiac markers, kidney disease)
Cancer screening (via tumor markers like PSA, CEA, AFP)
Pregnancy and fertility (hCG, LH tests)
Environmental and food safety
Essential in rural or underserved areas without access to centralized labs.
Early detection of disease leads to better outcomes, reduced hospitalizations, and lower healthcare costs.
Can be integrated with smartphone apps or reader devices for enhanced accuracy, tracking, and remote monitoring.
Widely used and trusted globally with decades of use in diagnostics—especially in public health campaigns and pandemic response.
Fluorescent LFA vs Traditional Testing
OncoFirm Diagnostics | https://oncofirm.com 1. Executive Summary Early detection of cancer remains one of the most cost-effective, life-saving interventions in modern medicine. However, millions globally still lack access to timely,…